JP2002514060A5 - - Google Patents

Download PDF

Info

Publication number
JP2002514060A5
JP2002514060A5 JP1998524007A JP52400798A JP2002514060A5 JP 2002514060 A5 JP2002514060 A5 JP 2002514060A5 JP 1998524007 A JP1998524007 A JP 1998524007A JP 52400798 A JP52400798 A JP 52400798A JP 2002514060 A5 JP2002514060 A5 JP 2002514060A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998524007A
Other languages
English (en)
Japanese (ja)
Other versions
JP4672092B2 (ja
JP2002514060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from US08/975,080 external-priority patent/US6245523B1/en
Publication of JP2002514060A publication Critical patent/JP2002514060A/ja
Publication of JP2002514060A5 publication Critical patent/JP2002514060A5/ja
Application granted granted Critical
Publication of JP4672092B2 publication Critical patent/JP4672092B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP52400798A 1996-11-20 1997-11-20 細胞アポトーシスを阻害するタンパク質であるサービビン(Survivin)、およびその調節 Expired - Lifetime JP4672092B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3143596P 1996-11-20 1996-11-20
US60/031,435 1996-11-20
US08/975,080 US6245523B1 (en) 1996-11-20 1997-11-20 Survivin, a protein that inhibits cellular apoptosis, and its modulation
US08/975,080 1997-11-20
PCT/US1997/021880 WO1998022589A2 (en) 1996-11-20 1997-11-20 Survivin, a protein that inhibits cellular apoptosis, and its modulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008328816A Division JP2009073860A (ja) 1996-11-20 2008-12-24 細胞アポトーシスを阻害するタンパク質であるサービビン(Survivin)、およびその調節

Publications (3)

Publication Number Publication Date
JP2002514060A JP2002514060A (ja) 2002-05-14
JP2002514060A5 true JP2002514060A5 (enExample) 2005-12-08
JP4672092B2 JP4672092B2 (ja) 2011-04-20

Family

ID=26707241

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52400798A Expired - Lifetime JP4672092B2 (ja) 1996-11-20 1997-11-20 細胞アポトーシスを阻害するタンパク質であるサービビン(Survivin)、およびその調節
JP2008328816A Pending JP2009073860A (ja) 1996-11-20 2008-12-24 細胞アポトーシスを阻害するタンパク質であるサービビン(Survivin)、およびその調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008328816A Pending JP2009073860A (ja) 1996-11-20 2008-12-24 細胞アポトーシスを阻害するタンパク質であるサービビン(Survivin)、およびその調節

Country Status (10)

Country Link
US (7) US6245523B1 (enExample)
EP (1) EP0950103B1 (enExample)
JP (2) JP4672092B2 (enExample)
KR (1) KR100645448B1 (enExample)
AT (1) ATE414149T1 (enExample)
AU (1) AU736587B2 (enExample)
CA (1) CA2271783C (enExample)
DE (1) DE69739105D1 (enExample)
IL (1) IL130036A (enExample)
WO (1) WO1998022589A2 (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
AU749348B2 (en) * 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
US20030033621A1 (en) * 1997-02-26 2003-02-13 De La Monte Suzanne Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
US7226730B1 (en) * 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
EP1066527A2 (en) 1998-04-01 2001-01-10 Yale University Method to identify modulators of survivin - tubulin interaction
AU4990999A (en) * 1998-07-14 2000-02-07 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
AU2003205017B2 (en) * 1998-09-29 2005-12-15 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
AU784884B2 (en) * 1999-12-10 2006-07-20 Anticancer, Inc. Methods for introducing genes into mammalian subjects
US6509162B1 (en) 2000-02-29 2003-01-21 Yale University Methods for selectively modulating survivin apoptosis pathways
WO2002002622A2 (en) * 2000-06-29 2002-01-10 The Salk Institute For Biological Studies Crystal structure of survivin
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
JP4368110B2 (ja) 2001-01-12 2009-11-18 エール ユニヴァーシティ 癌患者の生物学的流体中のサバイビンの検出
DE10102722A1 (de) * 2001-01-22 2002-08-14 Medinnova Ges Med Innovationen Verfahren und Testsystem zum Auffinden von Nervenzell-schützenden Substanzen
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20040102395A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of IAP-like expression
US8008003B2 (en) * 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
AU2003294540A1 (en) * 2002-12-24 2004-07-22 Saeid Babaei Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
PT2359841E (pt) * 2003-01-30 2015-02-10 Survac Aps Péptidos derivados de survivina e a sua utilização
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
DE602004017426D1 (de) * 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
ES2345200T3 (es) * 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
JP2007506442A (ja) * 2003-05-30 2007-03-22 ゲノミック ヘルス, インコーポレイテッド Egfr阻害薬への応答に関する遺伝子発現マーカー
JP4579911B2 (ja) * 2003-06-03 2010-11-10 アイシス・ファーマシューティカルズ・インコーポレイテッド スルビビン発現の調節
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
JP2007509613A (ja) * 2003-10-16 2007-04-19 ジェノミック ヘルス, インコーポレイテッド 遺伝子発現プロファイリングのためのqRT−PCRアッセイシステム
JP4926714B2 (ja) 2003-11-19 2012-05-09 サーバック エーピーエス Bcl−2ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
WO2005064019A2 (en) * 2003-12-23 2005-07-14 Genomic Health, Inc. Universal amplification of fragmented rna
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス, インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
EP1824975B9 (en) 2004-11-09 2011-04-20 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
EP1809316B1 (en) 2004-11-12 2008-12-31 VIB vzw Use of survivin to treat kidney failure
WO2006069192A1 (en) * 2004-12-22 2006-06-29 The Gillette Company Reduction of hair growth with survivin inhibitors
DK1853305T3 (en) 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
WO2006091666A2 (en) * 2005-02-23 2006-08-31 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
EP2312315A1 (en) 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
US7272013B1 (en) * 2005-07-28 2007-09-18 American Megatrends, Inc. Interchangeable design support system
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US7812173B2 (en) * 2005-08-23 2010-10-12 E.I. Du Pont De Nemours And Company Tetrahydro-1,8-dioxa-4a-aza-naphthalenes in coating applications
US20070049752A1 (en) * 2005-08-23 2007-03-01 Drysdale Neville E Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007082144A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and survivin in cancer
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
AU2007353412A1 (en) * 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
US8002827B2 (en) * 2007-04-24 2011-08-23 Abbott Medical Optics Inc. Systems and methods for ocular measurements
US9216080B2 (en) 2007-08-27 2015-12-22 Amo Groningen B.V. Toric lens with decreased sensitivity to cylinder power and rotation and method of using the same
US8974526B2 (en) * 2007-08-27 2015-03-10 Amo Groningen B.V. Multizonal lens with extended depth of focus
CA2699794C (en) 2007-09-10 2016-07-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
ATE523810T1 (de) 2008-02-15 2011-09-15 Amo Regional Holdings System, brillenglas und verfahren zur erweiterung der fokustiefe
US8439498B2 (en) 2008-02-21 2013-05-14 Abbott Medical Optics Inc. Toric intraocular lens with modified power characteristics
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
AU2009232774B2 (en) * 2008-03-31 2014-05-29 Tella Inc. Partial peptide of Survivin presented on MHC class II molecule and use thereof
US8862447B2 (en) 2010-04-30 2014-10-14 Amo Groningen B.V. Apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses
EP2512372B1 (en) 2009-12-18 2020-04-29 AMO Groningen B.V. Ophthalmic lens with angular varying phase delay
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
EP2646872A1 (en) 2010-12-01 2013-10-09 AMO Groningen B.V. A multifocal lens having an optical add power progression, and a system and method of providing same
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
CA2877203A1 (en) 2012-12-04 2014-06-12 Amo Groningen B.V. Lenses, systems and methods for providing binocular customized treatments to correct presbyopia
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2014153636A1 (en) 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
EP3470081A1 (en) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
EP3083663A1 (en) * 2013-12-16 2016-10-26 Merck Patent GmbH Survivin-directed cancer vaccine therapy
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
WO2016179573A1 (en) * 2015-05-07 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Variant survivin vaccine for treatment of cancer
KR102773176B1 (ko) * 2015-09-04 2025-02-27 헬스 리서치 인코포레이티드 암 치료용 안티-서비빈 항체
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
US11160861B2 (en) 2015-11-18 2021-11-02 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant
EP3413839B1 (en) 2016-02-09 2025-12-31 AMO Groningen B.V. Progressive intraocular lens and its methods of use and manufacture
AU2017237095B2 (en) 2016-03-23 2022-08-04 Johnson & Johnson Surgical Vision, Inc. Ophthalmic apparatus with corrective meridians having extended tolerance band
WO2017165660A1 (en) 2016-03-23 2017-09-28 Abbott Medical Optics Inc. Ophthalmic apparatus with corrective meridians having extended tolerance band
US11060087B2 (en) * 2016-06-15 2021-07-13 The Regents Of The University Of California Synthetic promoters for high throughput screening and gene modulation
WO2018078439A2 (en) 2016-10-25 2018-05-03 Amo Groningen B.V. Realistic eye models to design and evaluate intraocular lenses for a large field of view
US10739227B2 (en) 2017-03-23 2020-08-11 Johnson & Johnson Surgical Vision, Inc. Methods and systems for measuring image quality
EP3687447A1 (en) 2017-11-30 2020-08-05 AMO Groningen B.V. Intraocular lenses that improve post-surgical spectacle independent and methods of manufacturing thereof
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US11886046B2 (en) 2019-12-30 2024-01-30 Amo Groningen B.V. Multi-region refractive lenses for vision treatment
EP4333685B1 (en) 2021-05-05 2026-01-14 AMO Groningen B.V. Ring halometer system and method for quantifying dysphotopsias
CA3241303A1 (en) 2021-12-03 2023-06-08 Amo Groningen B.V. Lenses having multi-ring design for vision treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6238875B1 (en) * 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
US6070969A (en) * 1994-03-23 2000-06-06 Hewlett-Packard Company Thermal inkjet printhead having a preferred nucleation site
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
DE69739105D1 (de) 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
EP1066527A2 (en) * 1998-04-01 2001-01-10 Yale University Method to identify modulators of survivin - tubulin interaction
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US6509162B1 (en) * 2000-02-29 2003-01-21 Yale University Methods for selectively modulating survivin apoptosis pathways
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
JP4368110B2 (ja) * 2001-01-12 2009-11-18 エール ユニヴァーシティ 癌患者の生物学的流体中のサバイビンの検出
WO2003039536A1 (en) * 2001-11-07 2003-05-15 Yale University Enhancement of taxane-based chemotherapy by a cdk1 antagonist
WO2004054516A2 (en) * 2002-12-13 2004-07-01 The Ohio State University Antagonists for human prolactin
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins

Similar Documents

Publication Publication Date Title
JP2000506259A5 (enExample)
JP2000501599A5 (enExample)
JP2000515994A5 (enExample)
JP2000505441A5 (enExample)
JP2000507775A5 (enExample)
JP2000511019A5 (enExample)
JP2000513536A5 (enExample)
JP2000510124A5 (enExample)
JP2000503853A5 (enExample)
JP2000504267A5 (enExample)
JP2002515145A5 (enExample)
JP2000503140A5 (enExample)
JP2000507499A5 (enExample)
JP2000503216A5 (enExample)
JP2000505405A5 (enExample)
JP2000508994A5 (enExample)
JP2000504186A5 (enExample)
JP2001527517A5 (enExample)
JP2000508259A5 (enExample)
JP2000505983A5 (enExample)
JP2001502609A5 (enExample)
JP2001506915A5 (enExample)
JP2001507488A5 (enExample)
JP2000514107A5 (enExample)
JP2000507264A5 (enExample)